탈회골기질(DBM) 시장 : 예측(2026-2031년)

Demineralized Bone Matrix Market is forecasted to grow at a 4.98% CAGR, increasing from USD 1.224 billion in 2025 to USD 1.638 billion in 2031.

The demineralized bone matrix (DBM) market represents a significant segment within the broader orthobiologics and bone graft substitutes industry. DBM is an allograft material processed from human bone to remove its mineral content while retaining osteoinductive proteins and collagenous structure. It functions as a bone void filler and biologic enhancer in skeletal reconstruction, occupying a critical niche between purely osteoconductive synthetics and more complex cellular bone grafts.

Core Product Function and Clinical Rationale

DBM's primary value lies in its osteoinductive potential-the ability to stimulate host stem cells to differentiate into bone-forming osteoblasts. This biological activity, derived from retained bone morphogenetic proteins (BMPs) and growth factors, differentiates it from inert bone graft extenders. Its demineralized, pliable form allows for moldability to fit complex defect geometries. Clinically, DBM is utilized as a graft extender or enhancer in a variety of procedures, most notably spinal fusions, fracture non-unions, and dental/craniomaxillofacial reconstructions, where it supports the natural healing cascade.

Primary Market Growth Drivers

Market expansion is underpinned by a powerful demographic driver: the global aging population. Older adults exhibit a higher prevalence of osteoporosis, degenerative joint disease, and fragility fractures, all of which increase the volume of orthopedic and spinal fusion procedures. This aging demographic ensures a sustained and growing patient base requiring bone grafting solutions to achieve skeletal union, thereby driving consistent demand for DBM as a biologic adjunct.

Parallel to this, the rising incidence of bone-related disorders and trauma, coupled with increasing patient expectations for functional recovery, bolsters procedural volumes. Conditions such as spinal degeneration, non-healing fractures, and significant bone loss following trauma or tumor resection necessitate grafting materials that actively promote healing, supporting the use of osteoinductive agents like DBM.

Technological and processing advancements within the field are key growth vectors. Innovations focus on enhancing the consistency, bioactivity, and handling characteristics of DBM products. This includes improvements in donor screening, processing techniques to preserve growth factor efficacy, and the development of specialized carrier formulations (e.g., gels, putties, strips) that improve surgeon usability and ensure product retention at the surgical site. Research into combining DBM with synthetic scaffolds or other biologics to create optimized composite grafts also represents a forward-looking driver.

The significant and sustained procedural volume within hospital settings, particularly for spinal fusions and complex orthopedic revisions, consolidates DBM's market position. Hospitals serve as the central hub for these surgeries, driven by established surgical protocols, access to supporting technologies (e.g., imaging, navigation), and often favorable reimbursement pathways for allograft-based procedures compared to higher-cost alternatives.

Key Application Segments: Spine and Dental

Two application segments are particularly prominent. The spinal fusion segment represents a core market, where DBM is extensively used as an autograft extender or substitute in posterolateral and interbody fusions to promote arthrodesis. Clinical adoption is supported by its integration into standard surgical workflows for degenerative spine conditions.

The dental application segment is also a major and growing area of use. In oral and maxillofacial surgery, DBM is employed for alveolar ridge preservation, socket grafting following extraction, and sinus lift procedures in preparation for dental implants. Its biologic properties are valued for promoting quality bone regeneration in these sites, and its availability in easy-to-handle forms makes it well-suited for dental surgical practice.

Geographic Landscape and Regional Dynamics

North America maintains a dominant position in the DBM market. This leadership is attributed to a high volume of elective orthopedic and spinal procedures, a well-established tissue banking and allograft processing infrastructure, favorable reimbursement frameworks, and early surgeon adoption of advanced biologic materials. The region's sophisticated healthcare ecosystem supports both supply and demand.

The Asia-Pacific region is identified as a high-growth market with significant expansion potential. This is driven by improving healthcare infrastructure, rising medical tourism, growing adoption of advanced surgical techniques, and increasing healthcare expenditure in populous countries. Government initiatives to modernize medical device regulations and attract foreign investment further stimulate market development and local manufacturing capabilities in the region.

Competitive Landscape and Strategic Focus

The competitive environment includes specialized orthobiologics companies, large orthopedic device firms with biologics divisions, and tissue processing organizations. Competition centers on product portfolio breadth, consistency of osteoinductive potential, carrier technology, and strong surgeon relationships through dedicated sales and medical education teams.

Strategic initiatives are focused on product differentiation through proprietary processing methods, combination products (e.g., DBM with stem cells or synthetic granules), and securing clinical data to support claims of fusion efficacy. Companies also invest in streamlining supply chains from tissue donation to finished product distribution to ensure reliability and scale.

Future Market Trajectory

The future trajectory of the DBM market is oriented toward greater product refinement and evidence-based application. Continued research will aim to better quantify and standardize the osteoinductive potential of different DBM formulations, moving toward more predictable performance. Innovation in delivery systems and combination products will seek to address limitations in handling and retention in challenging surgical sites.

The market will also be influenced by the competitive landscape of bone graft substitutes, including the growth of synthetic alternatives and other advanced biologics. DBM's position will depend on its ability to demonstrate cost-effective biologic augmentation in routine procedures while continuing to serve as a foundational component in complex bone healing scenarios. As a well-established biologic workhorse, DBM is poised for steady growth, reinforced by demographic trends and its entrenched role in the surgical management of bone defects across orthopedic, spinal, and dental specialties.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Demineralized Bone Matrix Market Segmentation

• By Product
• Gel
• Putty
• Paste
• Graft
• Others
• By Material
• Human DBM
• Animal DBM
• Synthetic DBM
• By Application
• Spinal Fusion
• Dental / Maxillofacial Surgery
• Trauma Surgery
• Joint Reconstruction
• Others
• By End-User
• Hospitals
• Orthopedic Clinics
• Ambulatory Surgical Centers
• Others
• By Geography
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• Japan
• India
• South Korea
• Taiwan
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. DEMINERALIZED BONE MATRIX MARKET BY PRODUCT

• 5.1. Introduction
• 5.2. Gel
• 5.3. Putty
• 5.4. Paste
• 5.5. Graft
• 5.6. Others

6. DEMINERALIZED BONE MATRIX MARKET BY MATERIAL

• 6.1. Introduction
• 6.2. Human DBM
• 6.3. Animal DBM
• 6.4. Synthetic DBM

7. DEMINERALIZED BONE MATRIX MARKET BY APPLICATION

• 7.1. Introduction
• 7.2. Spinal Fusion
• 7.3. Dental / Maxillofacial Surgery
• 7.4. Trauma Surgery
• 7.5. Joint Reconstruction
• 7.6. Others

8. DEMINERALIZED BONE MATRIX MARKET BY END-USER

• 8.1. Introduction
• 8.2. Hospitals
• 8.3. Orthopedic Clinics
• 8.4. Ambulatory Surgical Centers
• 8.5. Others

9. DEMINERALIZED BONE MATRIX MARKET BY GEOGRAPHY

• 9.1. Introduction
• 9.2. North America
  • 9.2.1. By Product
  • 9.2.2. By Material
  • 9.2.3. By Application
  • 9.2.4. By End-User
  • 9.2.5. By Country
    • 9.2.5.1. USA
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
• 9.3. South America
  • 9.3.1. By Product
  • 9.3.2. By Material
  • 9.3.3. By Application
  • 9.3.4. By End-User
  • 9.3.5. By Country
    • 9.3.5.1. Brazil
    • 9.3.5.2. Argentina
    • 9.3.5.3. Others
• 9.4. Europe
  • 9.4.1. By Product
  • 9.4.2. By Material
  • 9.4.3. By Application
  • 9.4.4. By End-User
  • 9.4.5. By Country
    • 9.4.5.1. United Kingdom
    • 9.4.5.2. Germany
    • 9.4.5.3. France
    • 9.4.5.4. Spain
    • 9.4.5.5. Others
• 9.5. Middle East and Africa
  • 9.5.1. By Product
  • 9.5.2. By Material
  • 9.5.3. By Application
  • 9.5.4. By End-User
  • 9.5.5. By Country
    • 9.5.5.1. Saudi Arabia
    • 9.5.5.2. UAE
    • 9.5.5.3. Others
• 9.6. Asia Pacific
  • 9.6.1. By Product
  • 9.6.2. By Material
  • 9.6.3. By Application
  • 9.6.4. By End-User
  • 9.6.5. By Country
    • 9.6.5.1. China
    • 9.6.5.2. Japan
    • 9.6.5.3. India
    • 9.6.5.4. South Korea
    • 9.6.5.5. Taiwan
    • 9.6.5.6. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 10.1. Major Players and Strategy Analysis
• 10.2. Market Share Analysis
• 10.3. Mergers, Acquisitions, Agreements, and Collaborations
• 10.4. Competitive Dashboard

11. COMPANY PROFILES

• 11.1. Medtronic plc
• 11.2. Zimmer Biomet Holdings, Inc.
• 11.3. Stryker Corporation
• 11.4. DePuy Synthes
• 11.5. Exactech, Inc.
• 11.6. SeaSpine Holdings Corporation
• 11.7. Straumann Group
• 11.8. NuVasive, Inc.

12. APPENDIX

• 12.1. Currency
• 12.2. Assumptions
• 12.3. Base and Forecast Years Timeline
• 12.4. Key Benefits for the Stakeholders
• 12.5. Research Methodology
• 12.6. Abbreviations